Combination treatment of ONO-7475 with venetoclax exhibited potent cytotoxicity against FLT3-mutant AML cell lines and primary cells, including those resistant to venetoclax, particularly those overexpressing MCL-1 [140]. The gene discussed is FLT3; the disease is acute myeloid leukemia.